Tumor DNA (Deoxyribose Nucleic Acid) vaccine and virus vector vaccine taking mucoprotein 1 and surviving as targets

Abstract

The invention relates to the field of tumor DNA (Deoxyribose Nucleic Acid) vaccines and virus vector vaccines, and in particular relates to recombinant DNA vectors VR-S8 and VR-MS, recombinant adenoviruses AD-S8 and Ad-MS and a recombinant poxvirus MVA-MS vaccine, as well as application of DNA vaccines and optimized combination of immunization ways between virus vector vaccines to preparation of antitumor vaccines.

Description

[0001] This application is a divisional application, the original application date is December 4, 2009, the application number is 200910252427.X, and the name is "tumor DNA vaccine and virus vector vaccine targeting mucin 1 and survivin" . technical field [0002] The invention relates to the field of tumor DNA vaccine and virus vector vaccine. Specifically, the present invention relates to recombinant DNA vector VR-S8 and VR-MS, recombinant adenovirus Ad-S8 and Ad-MS and recombinant poxvirus MVA-MS vaccine, and DNA vaccine and viral vector vaccine and viral vector vaccine The application of the optimized combination of immunization methods in the preparation of anti-tumor vaccines. Background technique [0003] Survivin is a member of the inhibitor of apoptosis protein (IAP) family, has dual functions of anti-apoptosis and regulation of cell division, and is widely expressed in various embryonic tissues and cancer cells, but not in normal terminally differentiated cells ....

AI Technical Summary

Problems solved by technology

From the discovery of MUC1 to the present, a lot of vaccine research work has been carried out with it, and some vaccines have entered the stage of human clinical research, but most of them are traditional polypeptide, protein or dendritic cell (DC) vaccines, Most of these vaccines have problems such as poor immunogenicity or difficulty in preparation; the genetic vaccines that have entered the clinic are mainly recombinant poxvirus vaccines. Although no toxicity has been detected, there are still relatively large safety hazards in primary vaccination-boosting of recombinant poxvirus vaccines directly. , and the clinical effect is not very satisfactory; DNA carrier vaccine is still basically in the preclinical research stage due to its weak immunogenicity

[0008] The previous studies of the inventors of the present invention have shown that increasing the number of VNTRs can enhance the immune effect of MUC1 to a certain extent (see Zhang S et al., 2008). For example, the immune response caused by 33 copies of the MUC1 VNTR tandem repeat sequence is significantly stronger than that caused by 2 Therefore, the present invention selects the tandem repeat sequence MUC1VNTR containing 33 as antigen to design a vaccine, and expresses it with S8 to construct a fusion expression vaccine to enhance the broad-spectrum of vaccine immunity. and effectiveness, the combination of survivin and MUC1VNTR for tumor therapy has not been reported

Images